EcoR1 Capital LLC Purchases New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

EcoR1 Capital LLC purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 334,380 shares of the company’s stock, valued at approximately $23,256,000. Structure Therapeutics makes up approximately 1.1% of EcoR1 Capital LLC’s holdings, making the stock its 17th biggest holding. EcoR1 Capital LLC owned approximately 0.55% of Structure Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC lifted its stake in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares in the last quarter. State of Wyoming purchased a new position in Structure Therapeutics in the 2nd quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Structure Therapeutics in the 4th quarter valued at about $127,000. Finally, Banque Cantonale Vaudoise purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $205,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $45.00 on Thursday. The company has a 50 day simple moving average of $43.09 and a 200-day simple moving average of $57.53. The company has a market capitalization of $3.20 billion, a P/E ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on GPCR shares. HC Wainwright decreased their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Wolfe Research initiated coverage on shares of Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Finally, BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.